Repligen's pre-clinical compound demonstrates anti-anxiety activity.

Reports that Repligen Corp. has reported pre-clinical data indicating that its proprietary compound RG2417 has anti-anxiety properties in animal models and may have activity in anxiety disorders. Aim of the pre-clinical study to evaluate the effects of uridine treatment in mouse models of anxiety, including open field locomotor activity, elevated plus-maze test and light/dark choice procedure; Data suggesting that RG2417 may have activity in anxiety disorders without impairment of general activities.